<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887130</url>
  </required_header>
  <id_info>
    <org_study_id>PM0259CA223B0</org_study_id>
    <nct_id>NCT03887130</nct_id>
  </id_info>
  <brief_title>Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer</brief_title>
  <official_title>Randomised Phase II Study of the Combination of Oral Vinorelbine With Capecitabine Versus Gemcitabine in Combination With Paclitaxel Versus Gemcitabine in Combination With Docetaxel as First Line Chemotherapy in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <brief_summary>
    <textblock>
      The aim of this international open-label randomized phase II trial is to evaluate the
      efficacy and safety of an all-oral combination and two all-intravenous combinations as
      first-line therapy for HER2-negative mBC patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Duration of the study, approximately 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vinorelbine-Capecitabine (arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral vinorelbine (OV) with capecitabine (CAP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine-Paclitaxel (arm B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gemcitabine (GEM) in combination with paclitaxel (PAC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine-Docetaxel (arm C)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gemcitabine (GEM) in combination with docetaxel (DOC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral vinorelbine</intervention_name>
    <description>Oral vinorelbine 60 mg/m² on day 1 &amp; day 8, for cycle 1, and then 80 mg/m² on day 1 &amp; day 8, every 3 weeks for subsequent cycles</description>
    <arm_group_label>Vinorelbine-Capecitabine (arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14</description>
    <arm_group_label>Vinorelbine-Capecitabine (arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine 1250 mg/m²</intervention_name>
    <description>Gemcitabine 1250 mg/m² on day 1 &amp; day 8</description>
    <arm_group_label>Gemcitabine-Paclitaxel (arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine 1000 mg/m²</intervention_name>
    <description>Gemcitabine: 1000 mg/m² on day 1 &amp; 8</description>
    <arm_group_label>Gemcitabine-Docetaxel (arm C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 175 mg/m² on day 1</description>
    <arm_group_label>Gemcitabine-Paclitaxel (arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m² on day 1</description>
    <arm_group_label>Gemcitabine-Docetaxel (arm C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the breast;

          -  Documented metastatic disease previously untreated by chemotherapy;

          -  HER2 negative (assessed by 0-1+ IHC or 2+ IHC with FISH-) on the primary tumor or on
             metastatic site;

          -  Karnofsky Performance Status 70%.

        Exclusion Criteria:

          -  Local relapse alone after conservative treatment or contra-lateral tumor;

          -  Patients with symptoms suggesting CNS involvement or leptomeningeal metastases;

          -  Concomitant hormonal therapy for metastatic breast cancer;

          -  Prior chemotherapy in the metastatic setting;

          -  Patients previously treated with a vinca-alkaloid, capecitabine, gemcitabine or
             taxanes;

          -  Prior severe and unexpected reaction to fluoropyrimidine therapy (with or without
             documented DPD deficiency) or known hypersensitivity to 5-fluorouracil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

